Imaging scans to see how well a breast cancer drug works
Part of Cancer, Skin clinical trials.
This study looks at how well a drug called trastuzumab deruxtecan works in people with HER2-low breast cancer that has spread to other parts of the body. It uses PET-CT scans to check the tumor's response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have breast cancer that is HER2-low (a specific type that tests as IHC 1+ or 2+ and is not amplified).
- Your cancer has spread to other parts of the body.
- Your doctor has decided that treatment with trastuzumab deruxtecan is appropriate for you.
- You are able to follow the study schedule and procedures, and you have signed a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new type of PET scan (called FAPI) to see if it can help predict how well T-DXd (Enhertu) works on breast cancer that has spread to the brain. Participants will get T-DXd as planned and have the scan before starting treatment.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This study is testing whether a special PET scan (HER2-PET) can help predict how well the drug T-DXd (also known as Enhertu) might work for your breast cancer. T-DXd is a targeted therapy that delivers chemotherapy directly to cancer cells with certain markers. The trial will check if the scan can identify which patients are more likely to benefit, which could help personalize treatment.
This trial uses a special PET scan to see if your breast cancer has low levels of a protein called HER2. This could help doctors choose the right treatment for you.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.